Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, is making Mohamed Muhsin, leading breast cancer market analyst, available for interviews regarding the surprising approval of Genentech's Avastin for the treatment of breast cancer.

The FDA approved the drug for breast cancer late on Friday, Feb. 23 and surprised many in the industry since the FDA advisory committee had voted against the approval in December. An August 2007 survey by Decision Resources found that a very high rate of oncologists prescribing Avastin off-label to treat metastatic breast cancer. In August of 2007, 79 percent of U.S. oncologists were using Avastin to treat breast cancer patients. This prescribing behavior is driven by familiarity with Avastin for colorectal cancer and non-small-cell lung cancer, and by the E2100 trial data presented at ASCO.

For those reporters covering this topic, Mr. Muhsin is available for questions regarding Avastin and its use in the breast cancer market including:

  -- What impact will the approval have on the breast cancer drug market?    -- What impact will the approval have on Avastin?    -- Will Avastin achieve record-breaking revenues?    -- How will the uptake by insurers and Medicare progress now that Avastin      is approved for breast cancer?    -- What lessons can be learned from the FDA's reaction to the E2100 trial?    -- What does Avastin's approval for breast cancer mean for other cancer      drugs in line for approval by the FDA?   

To speak with Mr. Muhsin, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

PR Newswire -- Feb. 26
First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Competitive Advantages Position GlaxoSmithKline's Novel Combination Therapy to Overtake Avodart as the Clinical Gold Standard for the Treatment of Benign Prostatic Hyperplasia by 2011

View Now